This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

INNATE PHARMA : Preclinical Data Opening New Perspectives For Development Of Lirilumab In Combination To Be Presented At ASH

  • Evidence for lirilumab single-agent activity in lymphoma
  • Demonstration of enhanced efficacy of anti-CD20 antibodies when combined with lirilumab
  • To be presented at ASH meeting, December 9, abstract available online now

MARSEILLE, France, Nov. 14, 2013 (GLOBE NEWSWIRE) -- Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces that a new set of preclinical data on lirilumab will be presented in a poster at the upcoming 55th ASH Annual Meeting (December 7-10, 2013) in New Orleans, LA:

"Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer Cells As Monotherapy and In Combination With Anti-CD20 Antibodies" Session Name: 625. Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents: Poster III Date: Monday, December 9, 2013 Presentation Time: 6:00 PM - 8:00 PM Location: Ernest N. Morial Convention Center, Hall G

The abstract is available on the meeting website.

Lirilumab is a natural killer (NK) cell checkpoint inhibitor undergoing clinical development with partner Bristol-Myers Squibb in Acute Myeloid Leukemia in monotherapy and in combination settings in solid tumors. The new preclinical results are from research conducted by Dr Holbrook Kohrt from Stanford University, Innate Pharma and CIML 1. They support the monotherapy activity of lirilumab in mouse models of lymphoma, through the enhancement of NK cell cytotoxicity. Furthermore, the new data showed that in combination with the anti-CD20 antibody rituximab*, lirilumab enhanced NK cell-mediated, antibody-dependent cellular cytotoxicity (ADCC) against lymphoma in vitro and in vivo in mouse models. Taken together, these data reinforce the rationale for the development of lirilumab in onco-hematology, and open new perspectives for the combination of lirilumab with antibody drugs active through ADCC.   

Nicolai Wagtmann, CSO of Innate Pharma, said: "What is particularly exciting and impressive about these new preclinical results is that we show that lirilumab, beyond single-agent activity, also enhanced the efficacy of rituximab in vivo through ADCC. These results raise the possibility that lirilumab may similarly enhance the ADCC-activity of other therapeutic antibodies currently marketed or in clinical development in cancer and other indications."

About lirilumab (IPH2102/BMS-986015):

Lirilumab is a fully human monoclonal antibody blocking interaction between Killer-cell immunoglobulin-like receptors (KIR) on NK cells with their ligands. Blocking these receptors facilitates activation of NK cells and, potentially, destruction of tumor cells by the latter.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs